Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,343,460
  • Shares Outstanding, K 145,719
  • Annual Sales, $ 9,836 M
  • Annual Income, $ 1,161 M
  • EBIT $ 2,539 M
  • EBITDA $ 3,066 M
  • 60-Month Beta -0.08
  • Price/Sales 2.17
  • Price/Cash Flow 8.00
  • Price/Book 1.31

Options Overview Details

View History
  • Implied Volatility 35.85% ( -2.37%)
  • Historical Volatility 20.29%
  • IV Percentile 83%
  • IV Rank 55.13%
  • IV High 47.65% on 07/25/24
  • IV Low 21.36% on 09/10/24
  • Put/Call Vol Ratio 1.84
  • Today's Volume 4,110
  • Volume Avg (30-Day) 2,769
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 66,299
  • Open Int (30-Day) 61,853

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 3.43
  • Number of Estimates 21
  • High Estimate 3.99
  • Low Estimate 3.26
  • Prior Year 2.95
  • Growth Rate Est. (year over year) +16.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
145.07 +0.96%
on 12/20/24
165.29 -11.38%
on 12/02/24
-9.53 (-6.11%)
since 11/20/24
3-Month
145.07 +0.96%
on 12/20/24
199.99 -26.76%
on 09/24/24
-52.89 (-26.53%)
since 09/20/24
52-Week
145.07 +0.96%
on 12/20/24
268.30 -45.41%
on 01/03/24
-101.69 (-40.98%)
since 12/20/23

Most Recent Stories

More News
Biogen Stock: Is BIIB Underperforming the Healthcare Sector?

Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.

XLV : 138.00 (+1.26%)
GILD : 92.57 (+1.62%)
BIIB : 146.47 (-0.62%)
Insider Sale: Head of Development of $BIIB (BIIB) Sells 110 Shares

Priya Singhal, the Head of Development of $BIIB ($BIIB), sold 110 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.0% of their...

BIIB : 146.47 (-0.62%)
Is Vertex Pharmaceuticals Stock Underperforming the Dow?

Despite Vertex Pharmaceuticals’ recent underperformance compared to the Dow Jones, Wall Street analysts remain moderately optimistic about the stock’s prospects.

VRTX : 397.27 (+0.16%)
$DOWI : 42,840.26 (+1.18%)
BIIB : 146.47 (-0.62%)
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over

The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes ( S&P 500, Nasdaq Composite , and...

COMP : 6.23 (+4.18%)
LULU : 379.42 (+1.57%)
INTC : 19.52 (+2.41%)
MRNA : 39.39 (-0.43%)
DXCM : 80.04 (+5.57%)
BIIB : 146.47 (-0.62%)
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?

Biogen has significantly underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

$SPX : 5,930.85 (+1.09%)
IBRN : 25.47 (+0.40%)
BIIB : 146.47 (-0.62%)
UCB and Biogen Announce Positive Phase 3 Results for Dapirolizumab Pegol in Treating Moderate-to-Severe Systemic Lupus Erythematosus

Dapirolizumab pegol demonstrated significant clinical improvements in systemic lupus erythematosus, advancing treatment options for affected patients.Quiver AI SummaryDapirolizumab pegol (DZP), an investigational...

BIIB : 146.47 (-0.62%)
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

BIIB : 146.47 (-0.62%)
Stocks Settle Mostly Higher on Tech Stock Strength and Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.71%. Stocks on Monday...

NVDA : 134.70 (+3.08%)
HSIC : 69.82 (+1.26%)
$SPX : 5,930.85 (+1.09%)
SMCI : 31.59 (+1.12%)
FOUR : 103.52 (+2.23%)
NKE : 76.94 (-0.21%)
OKTA : 83.28 (+1.95%)
$IUXX : 21,289.15 (+0.85%)
IQV : 197.27 (+3.00%)
QQQ : 518.66 (+0.87%)
ZNH25 : 108-310s (+0.33%)
TSLA : 421.06 (-3.46%)
Stocks Mostly Higher on Positive Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.43%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.91%. Stocks today are mostly higher...

NVDA : 134.70 (+3.08%)
$SPX : 5,930.85 (+1.09%)
SMCI : 31.59 (+1.12%)
FOUR : 103.52 (+2.23%)
NKE : 76.94 (-0.21%)
$IUXX : 21,289.15 (+0.85%)
IQV : 197.27 (+3.00%)
QQQ : 518.66 (+0.87%)
ZNH25 : 108-310s (+0.33%)
TSLA : 421.06 (-3.46%)
NGNE : 22.64 (+2.56%)
NEM : 38.28 (+3.40%)
Eisai and Biogen Receive Positive CHMP Opinion for Lecanemab to Treat Early Alzheimer’s Disease in Europe

Eisai and Biogen announced CHMP's positive opinion for lecanemab to treat early Alzheimer's disease in select patient groups.Quiver AI SummaryEisai Co., Ltd. and Biogen Inc. announced that the European...

BIIB : 146.47 (-0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 150.64
2nd Resistance Point 149.24
1st Resistance Point 147.86
Last Price 146.47
1st Support Level 145.08
2nd Support Level 143.68
3rd Support Level 142.30

See More

52-Week High 268.30
Fibonacci 61.8% 221.22
Fibonacci 50% 206.68
Fibonacci 38.2% 192.14
Last Price 146.47
52-Week Low 145.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar